ABSTRACT Using information gained from (i) the relative HPLC retention of an abnormal insulin present in the serum of a hyperinsulinemic diabetic patient and (ii) the loss of an Mbo II restriction site in one of the patient's insulin gene alleles, it was recently predicted that the mutant insulin contained a serine-forphenylalanine substitution at position B24 or B25. We have now prepared human [Ser4]insulin and [Ser5]insulin by solid-phase peptide synthesis -and semisynthesis using an improved approach whereby the protecting groups can be removed from the final product in a single step. During reversed-phase HPLC analysis, the two semisynthetic insulins were clearly separated from normal insulin and from each other. Analysis of the patient's immunoaffinity-purified serum insulin by HPLC and radioimmunoassay showed that the insulin eluted at the position of [Ser]24insulin and coeluted with the analog when the two were studied in admixture. Additional studies showed that [SernBa] The proposal that human insulin gene mutations might result in the biosynthesis and secretion of abnormal insulins with low biological activity and that these abnormal insulins might contribute to human diabetes has been considered for many years (1). Four years ago, a hyperinsulinemic diabetic patient (patient 1) who responded normally to exogenous insulin was identified, and it was proposed that the patient secreted an abnormal insulin resulting from a mutation within a single insulin gene allele (2, 3) . Chemical analysis of the insulin isolated from pancreatic tissue obtained during an operation to drain a pseudocyst showed that the abnormal insulin contained a leucinefor-phenylalanine substitution at position B24 or B25 (2), a finding confirmed by restriction mapping of the patient's leukocyte-derived DNA (4). As sizable amounts of pancreatic insulin from this patient were no longer available, and as the opportunity for studying insulin isolated from pancreatic tissue is rare, a reversed-phase HPLC system for separating and identifying immunoaffinity-purified samples of human serum insulin was developed (5). By using this system, coupled with radioimmunometric detection of the hormone and with analysis of the HPLC elution patterns of semisynthetic standards of human [LeuB"] In the course of these studies, two additional patients (patients 2 and 3) with clinical findings similar to those of the first were identified and their serum insulins were analyzed by HPLC (5). The results showed that the three patients secreted chemically distinct insulin variants that were clearly separated both from normal insulin and from each other on reversed-phase HPLC columns; in each case, the patient's serum insulin consisted of the corresponding abnormal insulin and normal human insulin in a ratio of about 9:1. Restriction mapping of the leukocyte DNA derived from patient 2 further showed that one of the patient's insulin gene alleles had undergone a mutation resulting in loss of the Mbo II restriction site (T-C-T-T-C) normally attributable to the DNA sequence encoding phenylalanine-24 and -25 of the human insulin B chain (T-T-C-T-T-C) (5); point mutations in either codon could result in substitution of phenylalanine by leucine (TTA, TTG, or CTC), isoleucine (ATC), valine (GTC), tyrosine (TAC), cysteine (TGC), or serine (TCC). As the serum insulin derived from this patient eluted very early from reversed-phase HPLC columns (indicating an exaggerated hydrophilic character relative to that of insulin), it was predicted that the patient's abnormal insulin had undergone a serinefor-phenylalanine substitution at position B24 or B25 (5).
The proposal that human insulin gene mutations might result in the biosynthesis and secretion of abnormal insulins with low biological activity and that these abnormal insulins might contribute to human diabetes has been considered for many years (1) . Four years ago, a hyperinsulinemic diabetic patient (patient 1) who responded normally to exogenous insulin was identified, and it was proposed that the patient secreted an abnormal insulin resulting from a mutation within a single insulin gene allele (2, 3) . Chemical analysis of the insulin isolated from pancreatic tissue obtained during an operation to drain a pseudocyst showed that the abnormal insulin contained a leucinefor-phenylalanine substitution at position B24 or B25 (2), a finding confirmed by restriction mapping of the patient's leukocyte-derived DNA (4) . As sizable amounts of pancreatic insulin from this patient were no longer available, and as the opportunity for studying insulin isolated from pancreatic tissue is rare, a reversed-phase HPLC system for separating and identifying immunoaffinity-purified samples of human serum insulin was developed (5) . By using this system, coupled with radioimmunometric detection of the hormone and with analysis of the HPLC elution patterns of semisynthetic standards of human [ LeuB"]insulin and [LeuB"]insulin, the patient's abnormal insulin (named insulin Chicago) was identified as human [LeuB25]_ insulin.
In the course of these studies, two additional patients (patients 2 and 3) with clinical findings similar to those of the first were identified and their serum insulins were analyzed by HPLC (5) . The results showed that the three patients secreted chemically distinct insulin variants that were clearly separated both from normal insulin and from each other on reversed-phase HPLC columns; in each case, the patient's serum insulin consisted of the corresponding abnormal insulin and normal human insulin in a ratio of about 9:1. Restriction mapping of the leukocyte DNA derived from patient 2 further showed that one of the patient's insulin gene alleles had undergone a mutation resulting in loss of the Mbo II restriction site (T-C-T-T-C) normally attributable to the DNA sequence encoding phenylalanine-24 and -25 of the human insulin B chain (T-T-C-T-T-C) (5); point mutations in either codon could result in substitution of phenylalanine by leucine (TTA, TTG, or CTC), isoleucine (ATC), valine (GTC), tyrosine (TAC), cysteine (TGC), or serine (TCC). As the serum insulin derived from this patient eluted very early from reversed-phase HPLC columns (indicating an exaggerated hydrophilic character relative to that of insulin), it was predicted that the patient's abnormal insulin had undergone a serinefor-phenylalanine substitution at position B24 or B25 (5) .
In this report, we describe (i) the semisynthesis of human 
MATERIALS AND METHODS
Synthesis of the COOH-Terminal B-Chain Octapeptides of Insulin Containing Serine-for-Phenylalanine Substitutions. The peptides a-CF3CO-Gly-Ser-Phe-Tyr-Thr-Pro-Lys-Thr and a-CF3CO-Gly-Phe-Ser-Tyr-Thr-Pro-Lys-Thr were prepared by solid-phase methods as described (6) using 2.1 g of chloromethylated styrene-divinylbenzene copolymer resin substituted with a-t-butyloxycarbonyl-O-benzyl-L-threonine to the extent of 0.48 mmol/g. a-CF3CO-glycine was prepared essentially as described by others (7) . Peptides cleaved from the resin with hydrofluoric acid in the presence of anisole were extracted into 10% (vol/vol) acetic acid and were gel-filtered on Bio-Gel P-2 using 3 M acetic acid; the respective major comAbbreviations: t-Boc, t-butyloxycarbonyl; DOP insulin, desoctapeptide insulin (des-GlyB23,pheB24,pheB25,TyrB26,TrB27,ProB28,LysB29,ThrB30-insulin).
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HPLC Analysis of Human Serum Insulin. Methods have been described for (i) the immunoaffinity purification of insulin from human serum, (ii) the preparation of samples for HPLC, (iii) the HPLC elution of insulins from reversed-phase C-18 columns (Altex, Berkeley, CA) using an isocratic mobile phase containing 29.7% acetonitrile in 0.10 M phosphoric acid/0.02 M triethylamine/0.05 M NaClO4 (adjusted to pH 3.0 with NaOH), and (iv) the radioimmunometric detection of fmol amounts of eluted insulin (5, 9) .
Biological Assay for Insulin-Stimulated Glucose Oxidation by Isolated Rat Adipocytes. Epididymal fat pads removed from 300-g Wistar rats were minced and incubated with shaking at 370C for 1 hr in Krebs-Ringer/Hepes buffer, pH 7.4, containing 4% (wt/vol) bovine serum albumin (which had been dialyzed overnight against the same buffer), 3 mM glucose, and type II collagenase (Worthington) at 3 mg/ml; 1.2 ml of the collagenase solution was used for each gram of tissue. The resulting suspension was filtered through nylon mesh and the cells were washed five times at 370C with 10-ml portions of the buffer lacking both glucose and enzyme. A cell suspension (1% by volume of isolated adipocytes) was prepared in the KrebsRinger/Hepes buffer supplemented with 4% bovine serum albumin/5 mM sodium pyruvate; 0.8-ml aliquots of the suspension were added to plastic scintillation vials containing 0.5 tkCi (Amersham) and insulin or insulin analogs at concentrations ranging from 0 to 1 ,uM. The cells were incubated at 37°C for 90 min under 95% 02/5% CO2 with shaking. At the end of the incubation, individual suspensions were acidified with a drop of sulfuric acid and were immediately capped with a second vial containing filter paper saturated with Hyamine hydroxide. After 1 hr of shaking at 370C, scintillation fluid was added to the vial containing the adsorbed CO2 and the vial was assayed for radioactivity.
RESULTS
Approaches to the semisynthesis of insulin analogs bearing amino acid substitutions in the COOH-terminal region of the insulin B chain most often rely on trypsin-catalyzed peptide bond formation between the COOH-terminal arginyl residue of desoctapeptide insulin and the NH2-terminal glycyl residue of a chemically synthesized octapeptide (10) . Although synthesis of the protected octapeptide can be accomplished by solution-phase techniques (8, 10, 11) , our procedures have relied on rapid and automated solid-phase methods (6) . Retention of a protecting group on lysine-B29 during cleavage of the peptide from the solid support, however, requires careful peptide design when solid-phase methods are used. Our earlier procedure, identified as Approach I in Fig. 1 , was based on incorporation of lysine into the peptide as its e-CF3CO derivative. Although enzyme-catalyzed coupling of the synthetic octapeptide to bis-tBoc-DOP insulin could then proceed readily, removal of protecting groups from the disulfide bond-containing product required two steps, one of which involved incubation in aqueous piperidine at pH 12 (6) . Our improved method, identified as Approach II in Fig. 1 , incorporates glycine-B23 as its CF3CO derivative and results in the synthesis of the a-CF3CO octapeptide with a free lysyl E-amino function. Subsequent protection of the E-amino function with the t-Boc group prior to treatment with piperidine yields a t-Boc-lysine-B29-protected peptide with a free NH2-terminal glycyl residue; enzyme-catalyzed peptide bond formation can then proceed as before. Although this approach requires an additional step, all reactions proceed with excellent yield. More important, the improved approach obviates the need for incubating the semisynthetic Solid-phase synthesis and purification of the octapeptides a-CF3CO-Gly-Ser-Phe-Tyr-Thr-Pro-Lys-Thr and a-CF3CO-GlyPhe-Ser-Tyr-Thr-Pro-Lys-Thr yielded homogeneous products with the expected amino acid compositions. Protection of the octapeptide lysyl E-amino groups and removal of protection from their glycyl a-amino groups resulted in derivatives yielding dansyl glycine after treatment with dansyl chloride, acid hydrolysis, and thin-layer chromatography (12) ; the absence of E-dansyl lysine in the acid hydrolysate showed the effectiveness of the sequential protection and protecting group removal procedures outlined in Approach II. Incubation of each of these peptides and bis-(t-Boc)-DOP insulin with trypsin in aqueous-organic solution then gave the tris-(t-Boc) semisynthetic insulin products. Fig. 2 a and b show the reversed-phase HPLC elution profiles obtained for aliquots of the reaction mixtures in which protecting groups were removed corresponding to the serine-B25 and -B24 octapeptides, respectively. In each case, only residual octapeptide, residual DOP insulin, and the semisynthetic insulin were observed after 24 hr of incubation. Coupling yields were 74% and 70%, respectively, for the serine-B24 and -B25 insulin analogs. The HPLC-derived time course for the trypsincatalyzed semisynthesis is shown (Fig. 2 Inset) . Notably, the reaction was nearly complete after 2 hr of incubation. The addition of a second aliquot of trypsin after 12 hr did not increase the yield of product, a result suggesting that thermodynamic equilibrium had indeed been reached and that the extent of peptide bond formation had not been limited by enzyme inactivation. Fig. 2c As the abnormal human insulin from patient 2 had a greatly exaggerated hydrophilic character, and as the corresponding human insulin gene had apparently undergone mutation at a nucleotide site corresponding to insulin residue B24 or B25, we predicted that the insulin variant was either human [SerB24]insulin or human [SerB5I]insulin (5) . Our synthesis of both insulin analogs as standards for comparison with the natural mutant insulin and our ability to detect fmol amounts of insulin by radioimmunoassay after HPLC separation permitted a direct test of our prediction. As shown in Fig. 3b , only about 4% of the patient's serum insulin eluted at the position taken by normal human insulin. The majority of the serum insulin eluted at a position identical to that of the serine-B24 human insulin analog. Chromatography of a mixture of the patient's serum insulin and the semisynthetic serine-B24 analog resulted in a single peak of immunoreactive insulin with neither asymmetry nor broadening, as shown in Fig. 3c . Furthermore, the small amount of normal insulin in the patient's serum remained well resolved even in the presence of the synthetic analog. On To understand the functional consequences of substituting serine for phenylalanine at positions 24 and 25 of the insulin B chain, we examined the biological activities of both semisynthetic insulin analogs. Fig. 4 (15), (ii) the ratio of normal to abnormal insulin in the patient's serum was about 0.04: 1 (Fig. 3b) (Fig. 4) (4-22 microunits/ml). Additional studies will be required to delineate the causes of diabetes in this patient and in others who secrete abnormal products of the human insulin gene. DISCUSSION Our prediction that an abnormal human insulin identified in the serum of a diabetic patient had serine rather than phenylalanine at position B24 or B25 (5) prompted us to synthesize and study both human [SerBM] insulin and human [SerB"]insulin.
The clear resolution of normal human insulin and the two serinesubstituted insulin analogs by our reversed-phase HPLC system and the cochromatography of the patient insulin with human [SerB24]insulin identify the patient's insulin variant as having a serine-for-phenylalanine replacement at position B24. These investigations have resulted in the structural identification of an abnormal insulin gene product associated with human diabetes: the previous example was the assignment of insulin Chicago as human [LeuBu] insulin (5) ; this study shows that insulin Los Angeles is human [SerB24]insulin. By using standard nomenclature, these two abnormal insulins can now be designated human insulin B25 (Phe -* Leu) and human insulin B24 (Phe --Ser), respectively. It is thus clear that insulin gene mutations resulting in amino acid substitutions at positions B24 and B25 can be associated with human diabetes, and that such substitutions can result in replacement of phenylalanine by both hydrophilic and hydrophobic amino acid residues.
As previously noted (2, 6), mutations resulting in insulins with amino acid substitutions in the evolution-invariant tetrapeptide sequence B23 to B26 can provide important clues with regard to both insulin structure-function relationships and the roles of particular amino acid side chains in insulin action. Although substitution of either phenylalanyl residue within this sequence by leucine (a hydrophobic residue) or by serine (a hydrophilic residue) results in analogs having lower than normal activity (refs. 6, 13, and 14; this report), the loss in activity is not equivalent for the B24 and B25 positional isomers: replacing phenylalanine-B25 (a residue with a side chain on the surface of the insulin monomer) with either amino acid yields analogs with only about 1% of normal potency, whereas replacing phenylalanine-B24 (a residue with an inwardly directed side chain; see refs. 13 and 16) with leucine or serine yields analogs with 10-20% of normal potency. As the relative hydrophobicities of the side-chain replacements play little role in determining the activities of the final products, the loss of a phenylalanyl side chain appears to be the specific cause of decreased activity in each case. For analogs with replacements at position B25, decreased activity likely results from the loss of a specific side-chain contact with the receptor (perhaps involving iW-orbital interactions between hormone and receptor aromatic ring systems); for analogs with replacements at position B24, decreased activity is probably due to conformational changes in the insulin monomer resulting from altered side-chain bulk, rather than from altered side-chain functionality (6, 8, 11, 17 
